Targeted drug delivery strategies for precision medicines

MT Manzari, Y Shamay, H Kiguchi, N Rosen… - Nature Reviews …, 2021 - nature.com
Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval

D Hwang, JD Ramsey, AV Kabanov - Advanced drug delivery reviews, 2020 - Elsevier
Over the last three decades, polymeric micelles have emerged as a highly promising drug
delivery platform for therapeutic compounds. Particularly, poorly soluble small molecules …

Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway

A Sanches-Silva, L Testai, SF Nabavi, M Battino… - Pharmacological …, 2020 - Elsevier
Cardiovascular diseases comprise of non-communicable disorders that involve the heart
and/or blood vessels and have become the leading cause of death worldwide with …

Autophagy modulators: mechanistic aspects and drug delivery systems

S Tavakol, M Ashrafizadeh, S Deng, M Azarian… - Biomolecules, 2019 - mdpi.com
Autophagy modulation is considered to be a promising programmed cell death mechanism
to prevent and cure a great number of disorders and diseases. The crucial step in designing …

Nanoparticle delivery systems with cell-specific targeting for pulmonary diseases

Z Deng, GT Kalin, D Shi… - American journal of …, 2021 - atsjournals.org
Respiratory disorders are among the most important medical problems threatening human
life. The conventional therapeutics for respiratory disorders are hindered by insufficient drug …

[HTML][HTML] Recent advances on nanoparticle-based therapies for cardiovascular diseases

RS Soumya, KG Raghu - Journal of Cardiology, 2023 - Elsevier
Nanoparticles are exclusively suitable for studying and developing potential therapies
against cardiovascular diseases (CVD) because of their size, fine-tunable properties, and …

mTOR signaling in pulmonary vascular disease: pathogenic role and therapeutic target

A Babicheva, A Makino, JXJ Yuan - International journal of molecular …, 2021 - mdpi.com
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease without a cure.
The exact pathogenic mechanisms of PAH are complex and poorly understood, yet a …

Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications

M Durymanov, T Kamaletdinova, SE Lehmann… - Journal of controlled …, 2017 - Elsevier
Over the past few decades, enhanced permeability of tumor vasculature was actively
exploited for targeted delivery of anticancer nanomedicines resulting in numerous …

Nanomedicine-mediated therapeutic approaches for pulmonary arterial hypertension

E Mirhadi, P Kesharwani, TP Johnston… - Drug Discovery Today, 2023 - Elsevier
Highlights•Nanomedicine has emerged as a field with great opportunities to improve
treatment strategies.•Pulmonary arterial hypertension (PAH) is a serious and incurable …

Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization

N Nafee, S Makled, N Boraie - European Journal of Pharmaceutical …, 2018 - Elsevier
With the non-selective vasodilating action, short half-life and first-pass metabolism of
sildenafil (SC), local application in the lung for pulmonary arterial hypertension is of high …